Clinical trials: Fibrosis, Liver, open to volunteers
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE)…
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Trial name
- LFMRECT (NCT06797596)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fibronostics USA, Inc
Steatohepatitis, Nonalcoholic, Steatosis of Liver
Ketogenic Diet in MASLD-related cACLD
The investigators hypothesize that very low ketogenic diet could represent a new therapeutic option in the management of patients with MASLD and cACLD.
- Conditions
- Steatohepatitis, Nonalcoholic, Steatosis of Liver, Cirrhosis, Liver
- Trial name
- NCT06537466
- Testing
- Mediterranean diet, Very Low Ketogenic Diet
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Palermo
Liver Cirrhosis, Gastrointestinal Bleeding
Utilizing of Physiological Parameters Predict the Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding
Can physiological indicators such as quick Sequential Organ Failure Assessment , Shock Index, and its derived indicators such as Modified Shock Index , Age Shock Index and Respiratory Adjusted Shock Index accurately predict the…
- Trial name
- SI (NCT06680583)
- Testing
- physical indicators such as shock index relatives
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- St. Martin De Porress Hospital
Cirrhosis, Liver, Splenectomy; Status
The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients
In this study, the investigators compared the improvement of liver reserve function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection.
- Conditions
- Cirrhosis, Liver, Splenectomy; Status, Portal Hypertension
- Trial name
- ELSDL (NCT05325437)
- Testing
- Laparoscopic splenectomy and azygoportal disconnection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Northern Jiangsu People's Hospital
Alcoholic Liver Cirrhosis
Long-Term Follow-up of Patients With Alcoholic Liver Cirrhosis Treated With Cellgram-LC
The goal of this observational study is to learn about the long-term safety of Cellgram-LC in patients with alcoholic liver cirrhosis who previously received Cellgram-LC in the PMC-P-07 study.
- Trial name
- NCT05093881
- Where
- 14 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Pharmicell Co., Ltd.
Ascites, Liver Cirrhosis
Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis
The purpose of this study is to learn whether a procedure called Proximal Splenic Artery Embolization (PSAE) can lower the need for repeat fluid drainage in adults with cirrhosis and a buildup of fluid in the abdomen (ascites)…
- Conditions
- Ascites, Liver Cirrhosis, Hypertension, Portal
- Trial name
- NCT07755059
- Testing
- Proximal Splenic Artery Embolization
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes, Liver Steatoses
Prevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes
The goal of this observational cross-sectional study is to assess the prevalence and stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), specifically liver steatosis and fibrosis in adults aged 18 and older…
- Conditions
- Type 1 Diabetes, Liver Steatoses, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
- Trial name
- STEA-DT1 (NCT07475962)
- Testing
- Adiposity and BMI Classification
- Volunteers
- 100 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
Autoimmune Liver Disease, Liver Transplant Disorder
A Study of SIPLIZUMAB in AILD and LT Patients
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including…
- Conditions
- Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Trial name
- SET-SAIL (NCT06455280)
- Testing
- Siplizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Elizabeth C. Verna
Liver Cirrhosis, Gastric Antral Vascular Ectasia
Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG Trial)
Gastric Antral Vascular Ectasia (GAVE) is an erosive form of gastritis distinguished by veno-capillary ectasia, which manifests as tortuous columns of dilated vessels.
- Trial name
- NCT06772480
- Testing
- Thalidomide, Argon Plasma Coagulation
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Chronic Liver Disease (CLD), Fibrosis of Liver
Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers
Morbidity and mortality of CLD is driven by the extent of liver fibrosis, characterized by scar formation and disruption of the normal liver architecture. HSCs play a central role in liver fibrosis development.
- Trial name
- NCT07359742
- Testing
- Blood draw for biomarkers
- Where
- Belgium
- Volunteers
- 110 people
- Sponsor
- Universitair Ziekenhuis Brussel
Advanced Hepatocellular Carcinoma, Cirrhosis
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
This phase Ib/II trial tests the safety, side effects, and best dose of zanzalintinib and how well it works in treating patients with hepatocellular (liver) cancer that may have spread from where it first started to nearby…
- Conditions
- Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT07042919
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Devalingam Mahalingam
Portal Hypertension Related to Cirrhosis
EUS-guided Response Assessment to NSBB
The goal of this clinical trial is to learn if endoscopic ultrasound (EUS)-guided portal pressure measurement can determine the treatment response to non-selective beta-blockers (NSBB) in patients with cirrhosis and clinically…
- Trial name
- NCT06513195
- Testing
- endoscopic ultrasound-guided portal pressure measurement
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cirrhosis, Splenectomy
Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.
- Conditions
- Cirrhosis, Splenectomy, Portal Vein Thrombosis, Hypertension, Portal
- Trial name
- NCT07461545
- Testing
- Apixaban 2.5 MG
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Northern Jiangsu People's Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.
- Trial name
- NCT06318169
- Testing
- Pegozafermin
- Where
- 370 sites in United States, Argentina and 25 more
- Volunteers
- 1,350 people
- Sponsor
- Hoffmann-La Roche
Primary Biliary Cholangitis (PBC)
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a…
- Trial name
- ELFIDENCE (NCT06016842)
- Testing
- Elafibranor
- Where
- 198 sites in United States, Argentina and 26 more
- Volunteers
- 276 people
- Sponsor
- Ipsen
Hepatocellular Carcinoma, Liver Cirrhosis
Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)
This prospective multicenter observational study evaluates the performance of a structured hepatocellular carcinoma (HCC) surveillance program in patients at increased risk of developing liver cancer.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Hepatitis B, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- Screening HCC (NCT07764835)
- Volunteers
- 300 people
- Sponsor
- D'Or Institute for Research and Education
Pediatric Non-alcoholic Fatty Liver Disease
Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic.
- Trial name
- NCT05309863
- Testing
- Lifestyle management
- Where
- 3 sites in Belgium
- Volunteers
- 850 people
- Sponsor
- University Hospital, Ghent
Chronic Liver Disease, Cirrhosis
An Observational Study of Patients With Chronic Liver Disease
TARGET-Liver Disease (TARGET-LD) is an observational research study to conduct a comprehensive review of outcomes for patients with chronic liver disease (CLD).
- Trial name
- NCT05744713
- Testing
- Observational
- Where
- 10 sites in United States
- Volunteers
- 500,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Cirrhosis, Liver
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Loss of skeletal muscle mass or sarcopenia is the most common and potentially reversible complication in cirrhosis that increases morbidity and mortality before, during and after liver transplantation.
- Trial name
- NCT03208868
- Testing
- Leucine enriched essential amino acid (EEA/LEU), Balanced amino acid supplement (BAA)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic